DNA secrets, gene editing, and personalized medicine.
CRISPR Therapeutics has released pivotal Phase 1a durability data for its in vivo gene editing therapy CTX310, showing sustained reductions in triglycerides and LDL cholesterol. The findings, presented at the ESC Congress 2026, mark a significant step toward single-dose treatments for cardiovascular disease.
CRISPR kilobase-scale DNA knock-in technology advances precision gene therapy for rare genetic diseases, while personalized treatment platforms aim to make customized therapies economically viable. A new center collaboration between leading institutions targets rare disease genetic medicines development.
Recent advances in gene therapy standardization and ancient DNA research are reshaping personalized medicine. CRISPR-based therapies continue expanding clinical approvals globally, while landmark studies reveal accelerated human evolution through analysis of 15,000+ ancient genomes.
This week brings major breakthroughs in standardizing personalized CRISPR therapies, advances in genome sequencing standards for precision medicine, and landmark findings on human evolution from ancient DNA analysis. A gene-editing company plans a major IPO, while researchers work to make gene therapies faster and more accessible to patients. <!-- /headline -->Standardizing CRISPR Therapies Unlocks Rare Disease Treatments at Scale<!-- /headline -->
Researchers have successfully edited essential genes in human embryos using base editing, raising important questions about IVF success rates and embryo viability. Meanwhile, a major international collaboration between Abu Dhabi and Children's Hospital of Philadelphia aims to accelerate gene-editing therapies for rare diseases, and the AI in genomics market is projected to reach $9.32 billion by 2030 as precision medicine adoption accelerates.
Prime editing advances move gene therapy closer to clinical use with improved efficiency and delivery. A fresh approach to personalizing CRISPR therapies for rare genetic diseases could make production economically viable. Long-read sequencing demonstrates improved diagnostic accuracy for rare disease detection.
Base editing in human embryos has demonstrated both promise and peril: researchers successfully corrected disease-causing mutations but also inadvertently created new variants, raising clinical and ethical concerns. Meanwhile, the FDA has issued new draft guidance to accelerate gene therapies for rare genetic diseases, and Element Biosciences secured $175M to expand genomics platform adoption.
Landmark developments in gene editing and personalized therapies are accelerating clinical applications, while FDA guidance enables shared data across CRISPR programs. A breakthrough in base editing of human embryos sparks both excitement and regulatory concern over timeline to clinic.
The FDA released draft guidance for gene therapy products incorporating genome editing, establishing a clearer regulatory pathway for developers. Meanwhile, CRISPR-based platforms continue advancing toward personalized medicine applications, with multiple clinical trials demonstrating safety and efficacy in rare genetic diseases and metabolic disorders.
Gene editing markets surge as personalized CRISPR therapies advance toward clinical scale, while Eli Lilly's base editor shows promising early cholesterol reduction results. Meanwhile, landmark ancient-genome studies reveal accelerated human evolution and complex Indigenous American ancestry patterns.
This week's edition covers a new market report projecting the global genome editing industry will reach $55.7 billion by 2035, a wave of fresh FDA regulatory decisions in genomic diagnostics, and Oxford Nanopore's preview of next-generation sequencing and proteomics tools. Fresh clinical and regulatory signals point to accelerating momentum in liquid biopsy, companion diagnostics, and bioinformatics infrastructure.
This week's genetics and genomics landscape is shaped by fresh regulatory milestones from the FDA, a wave of new companion diagnostic approvals in oncology, and a growing market outlook for genome editing that projects the sector reaching $55.7 billion by 2035. The genomics workforce is also expanding to meet surging clinical demand, with educational institutions ramping up genetics programs. Key FDA actions on liquid biopsy and ctDNA-guided therapy mark a turning point for precision oncology.
This week's genomics landscape is headlined by a major market forecast placing the global genome editing sector on a path to $55.7 billion by 2035, fresh FDA approvals across companion diagnostics, and new regulatory momentum around laboratory-developed test oversight. Several clinical-stage developments from GenomeWeb's reporting round out a busy seven days for the field.
This week's most significant genetics story centers on what's next for personalized CRISPR gene editing after a landmark case-study in a newborn, with physician-scientists at CHOP discussing the horizon for bespoke therapies. On the genomics front, a deep multiomic profiling study reveals how molecular networks vary by ancestry and geography, while the FDA approves a new MRD-guided cancer therapy linked to a genomic companion diagnostic. The next-generation genome editing market is also drawing fresh analyst attention, projecting rapid expansion through 2035.
This week's top story is a breakthrough from UMass Chan Medical School, where scientists pioneered "prime assembly" — a gene editing technology capable of inserting exceptionally large DNA segments into the human genome with precision. ChristianaCare launched a nonprofit software company aimed at expanding access to gene-editing tools. The CRISPR market continues its rapid growth trajectory, with fresh forecasts projecting a 14.3% compound annual growth rate.
This week in genetics and genomics, a newly characterized CRISPR protein called Cas12a2 shows promise for destroying cancer cells and treating viral infections by shredding target cell DNA. Market reports confirm explosive growth trajectories for both CRISPR-based gene editing and personalized medicine, while GenomeWeb's latest headlines reveal patent battles and record revenues shaping the commercial genomics landscape.
This week in genetics and genomics, a new AI tool demonstrated it can reconstruct genetic ancestry from DNA mutation patterns in minutes, matching top statistical methods. Industry news from GenomeWeb reveals significant market movements, including GeneDx stock falling after Q1 disappointments and Tempus AI posting strong 36% revenue growth. A CRISPR-Cas9 Phase 1 trial targeting ANGPTL3 published in NEJM showed substantial reductions in the protein at higher doses, with a promising safety profile.
A landmark new genome-editing technology capable of inserting entire gene segments was reported in *Nature* this week, while Intellia Therapeutics announced its CRISPR treatment for hereditary angioedema cleared a pivotal Phase 3 trial. On the diagnostics and industry front, genomics giant J. Craig Venter has died at age 79, and Illumina raised its 2026 guidance on surging NovaSeqX demand.
This week's top genetics stories include a landmark OSU-led technology enabling "rewriting a chapter" of the genome published in *Nature*, Intellia Therapeutics' CRISPR-based hereditary angioedema therapy succeeding in Phase 3 trials, and fresh ancient-DNA research revealing a surprising multi-population origin for modern humans. The genomics industry also saw major business moves, including Biohub committing $500M to AI-based predictive cell models and the death of genomics pioneer J. Craig Venter at age 79.
This week's most significant genetics news centers on a landmark Phase 3 trial success for Intellia Therapeutics' CRISPR-based hereditary angioedema treatment, while new research reveals a vast Indigenous American genome map exposing previously unknown migrations and over a million new genetic variants. The FDA's "Plausible Mechanism Framework" continues to reshape how ultra-rare gene editing therapies reach patients, with fresh analysis published this week.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
